HSD17B12 gene rs11037575 C>T polymorphism confers neuroblastoma susceptibility in a Southern Chinese population

Figures & data

Table 1 Associations between selected polymorphisms and risk of neuroblastoma

Genotype	Cases (N=256), n (%)	Controls (N=531), n (%)	P-valuea	Crude OR (95% CI)	P-value	Adjusted OR (95% CI)b	P-valueb
DUSP12 rs1027702 T>C (HWE = 0.534)
TT	137 (53.52)	282 (53.11)		1.00		1.00
TC	98 (38.28)	206 (38.79)		0.98 (0.71–1.34)	0.896	0.98 (0.71–1.34)	0.887
CC	21 (8.20)	43 (8.10)		1.01 (0.57–1.76)	0.985	1.01 (0.58–1.78)	0.961
Additive			0.990	0.99 (0.79–1.25)	0.950	0.99 (0.79–1.26)	0.962
Dominant	119 (46.48)	249 (46.89)	0.914	0.98 (0.73–1.33)	0.914	0.98 (0.73–1.33)	0.915
Recessive	235 (91.80)	488 (91.90)	0.960	1.01 (0.59–1.75)	0.960	1.02 (0.59–1.77)	0.932
IL31RA rs10055201 A>G (HWE =0.511)
AA	69 (26.95)	153 (28.81)		1.00		1.00
AG	136 (53.13)	257 (48.40)		1.17 (0.83–1.67)	0.373	1.17 (0.82–1.67)	0.380
GG	51 (19.92)	121 (22.79)		0.94 (0.61–1.44)	0.760	0.92 (0.60–61.43)	0.719
Additive			0.442	0.98 (0.79–1.21)	0.851	0.97 (0.79–1.21)	0.810
Dominant	187 (73.05)	378 (71.19)	0.587	1.10 (0.79–1.53)	0.587	1.09 (0.78–1.53)	0.607
Recessive	205 (80.08)	410 (77.21)	0.362	0.84 (0.58–1.22)	0.363	0.83 (0.58–1.21)	0.333
DDX4 rs2619046 G>A (HWE =0.499)
GG	57 (22.27)	151 (28.44)		1.00		1.00
AG	132 (51.56)	257 (48.40)		1.36 (0.94–1.97)	0.103	1.36 (0.94–1.97)	0.101
AA	67 (26.17)	123 (23.16)		1.44 (0.94–2.21)	0.092	1.45 (0.95–2.22)	0.088
Additive			0.175	1.10 (0.97–1.48)	0.090	1.20 (0.97–1.49)	0.086
Dominant	199 (77.73)	380 (71.56)	0.066	1.39 (0.98–1.97)	0.067	1.39 (0.98–1.98)	0.065
Recessive	189 (73.83)	408 (76.84)	0.356	1.18 (0.83–1.66)	0.356	1.18 (0.84–1.67)	0.345
HSD17B12 rs11037575 C>T (HWE =0.026)
CC	144 (56.25)	263 (49.53)		1.00		1.00
CT	91 (35.55)	236 (44.44)		0.70 (0.51–0.97)	0.030	0.71 (0.51–0.97)	0.030
TT	21 (8.20)	32 (6.03)		1.20 (0.67–2.16)	0.545	1.19 (0.66–2.14)	0.565
Additive			0.049	0.89 (0.70–71.13)	0.334	0.89 (0.69–1.13)	0.327
Dominant	112 (43.75)	268 (50.47)	0.077	0.76 (0.57–1.03)	0.077	0.76 (0.57–1.03)	0.077
Recessive	235 (91.80)	499 (93.97)	0.254	1.39 (0.79–2.47)	0.255	1.38 (0.78–2.45)	0.270
Combined effect of risk genotypes
0	2 (0.78)	5 (0.94)		1.00		1.00
1	107 (41.80)	260 (48.96)		1.03 (0.20–25.39)	0.973	1.02 (0.19–5.33)	0.986
2	122 (47.66)	227 (42.75)		1.34 (0.26–27.03)	0.726	1.33 (0.25–26.94)	0.739
3	23 (8.98)	37 (6.97)		1.55 (0.28–8.68)	0.616	1.55 (0.28–8.66)	0.621
4	2 (0.78)	2 (0.38)		2.50 (0.19–32.19)	0.482	2.29 (0.18–29.69)	0.536
Trend			0.359	1.26 (1.01–1.58)	0.042	1.26 (1.01–1.58)	0.043
0–1	109 (42.58)	265 (49.91)		1.00		1.00
2–4	147 (57.42)	266 (50.09)	0.054	1.34 (1.00–01.82)	0.054	1.34 (0.99–1.81)	0.055

Notes: The values are in bold if the 95% CIs excluded 1 or P<0.05.

a χ² test for genotype distributions between neuroblastoma patients and controls.

b Adjusted for age and gender.

Abbreviations: CI, confidence interval; HWE, Hardy–Weinberg equilibrium; OR, odds ratio.

Table 2 Stratification analysis for association of HSD17B12 and combined genotypes with risk of neuroblastoma

Variables	rs11037575 (cases/controls)		Adjusted ORa (95% CI)	P-valuea	Combined (cases/controls)		Adjusted ORa (95% CI)	P-valuea
	CC	CT/TT			0–1	2–4
Age, months
≤18	63/117	38/116	0.60 (0.37–0.97)	0.036	46/118	55/115	1.22 (0.77–1.96)	0.399
>18	81/146	74/152	0.89 (0.60–61.31)	0.546	63/147	92/151	1.43 (0.96–2.12)	0.076
Gender
Female	59/113	44/120	0.70 (0.44–1.11)	0.131	40/119	63/114	1.65 (1.03–2.64)	0.039
Male	85/150	68/148	0.81 (0.55–1.20)	0.297	69/146	84/152	1.17 (0.79–1.73)	0.440
Sites of origin
Adrenal gland	25/263	21/268	0.83 (0.45–1.52)	0.545	17/265	29/266	1.71 (0.92–93.20)	0.091
Retroperitoneal	48/263	39/268	0.80 (0.51–1.26)	0.340	42/265	45/266	1.06 (0.68–1.68)	0.792
Mediastinum	56/263	34/268	0.59 (0.37–0.94)	0.025	41/265	49/266	1.19 (0.76–1.87)	0.443
Others	11/263	14/268	1.26 (0.56–2.82)	0.582	7/265	18/266	2.55 (1.05–06.23)	0.039
Clinical stages
I + II +4s	73/263	53/268	0.71 (0.48–1.06)	0.092	58/265	68/266	1.17 (0.79–1.73)	0.433
III + IV	67/263	54/268	0.78 (0.53–1.17)	0.229	45/265	76/266	1.69 (1.12–2.54)	0.012

Notes: The values are in bold if the 95% CIs excluded 1 or P<0.05.

a Adjusted for age and gender.

Abbreviations: CI, confidence interval; OR, odds ratio.

Table S1 General characteristics in neuroblastoma cases and controls

Variables	Cases (n=256)	Controls (n=531)	P-valuea
	N (%)	N (%)
Age range, months	0–156	0.07–156	0.239
Mean ± standard deviation	30.87±26.45	29.73±24.86
≤18	101 (39.45)	233 (43.88)
>18	155 (60.55)	298 (56.12)
Gender			0.333
Female	103 (40.23)	233 (43.88)
Male	153 (59.77)	298 (56.12)
Clinical stages
I	54 (21.09)
II	65 (25.39)
III	44 (17.19)
IV	77 (30.08)
4s	9 (3.52)
NA	7 (2.73)
Sites of origin
Adrenal gland	46 (17.97)
Retroperitoneal region	87 (33.98)
Mediastinum	90 (35.16)
Other region	25 (9.77)
NA	8 (3.13)

Note:

a Two-sided c² test for distributions between neuroblastoma cases and controls.

Abbreviation: NA, not available.